ES2243273T3 - Utilizacion terapeutica de d-treo-metilfenidato para el tratamiento del trastorno de hperactividad y deficit de atencion. - Google Patents
Utilizacion terapeutica de d-treo-metilfenidato para el tratamiento del trastorno de hperactividad y deficit de atencion.Info
- Publication number
- ES2243273T3 ES2243273T3 ES00940504T ES00940504T ES2243273T3 ES 2243273 T3 ES2243273 T3 ES 2243273T3 ES 00940504 T ES00940504 T ES 00940504T ES 00940504 T ES00940504 T ES 00940504T ES 2243273 T3 ES2243273 T3 ES 2243273T3
- Authority
- ES
- Spain
- Prior art keywords
- mph
- treatment
- dose
- study
- methylphenidate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960001344 methylphenidate Drugs 0.000 title claims abstract description 7
- 230000006735 deficit Effects 0.000 title claims description 4
- 230000001225 therapeutic effect Effects 0.000 title description 3
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000013403 hyperactivity Diseases 0.000 claims description 4
- 229960001042 dexmethylphenidate Drugs 0.000 claims description 3
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 claims description 3
- 206010028714 Narcolepsy and hypersomnia Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 206010067948 Compulsive shopping Diseases 0.000 claims 1
- 239000004081 narcotic agent Substances 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract description 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract description 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 230000000694 effects Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000003750 conditioning effect Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 229960002319 barbital Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000003137 locomotive effect Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004031 partial agonist Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000006550 Mydriasis Diseases 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000010411 postconditioning Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940099204 ritalin Drugs 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical class COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000872198 Serjania polyphylla Species 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- IXRNQIKIVWWFBH-UHFFFAOYSA-N n-(1-phenylethenyl)acetamide Chemical compound CC(=O)NC(=C)C1=CC=CC=C1 IXRNQIKIVWWFBH-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9913458.7A GB9913458D0 (en) | 1999-06-09 | 1999-06-09 | The therapeutic use of d-threo-methylphenidate |
| GB9913458 | 1999-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2243273T3 true ES2243273T3 (es) | 2005-12-01 |
Family
ID=10855048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00940504T Expired - Lifetime ES2243273T3 (es) | 1999-06-09 | 2000-06-08 | Utilizacion terapeutica de d-treo-metilfenidato para el tratamiento del trastorno de hperactividad y deficit de atencion. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1185268B1 (https=) |
| JP (1) | JP2003501387A (https=) |
| AT (1) | ATE302006T1 (https=) |
| AU (1) | AU766748B2 (https=) |
| CA (1) | CA2376215A1 (https=) |
| DE (1) | DE60022033T2 (https=) |
| ES (1) | ES2243273T3 (https=) |
| GB (1) | GB9913458D0 (https=) |
| WO (1) | WO2000074680A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US6486177B2 (en) | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| US6962997B1 (en) | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
| AU2006206410B2 (en) | 2005-01-20 | 2012-08-30 | Ampio Pharmaceuticals, Inc. | Methylphenidate derivatives and uses of them |
| EP2300011A4 (en) | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | THERAPEUTIC PROCESSES AND COMPOUNDS |
| US10662146B2 (en) | 2015-09-15 | 2020-05-26 | Praxis Bioresearch, LLC | Prodrugs of fencamfamine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9514451D0 (en) * | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
| US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
| US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| MX9805870A (https=) * | 1996-01-22 | 1999-01-31 | ||
| US6210705B1 (en) * | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| US6025502A (en) * | 1999-03-19 | 2000-02-15 | The Trustees Of The University Of Pennsylvania | Enantopselective synthesis of methyl phenidate |
-
1999
- 1999-06-09 GB GBGB9913458.7A patent/GB9913458D0/en active Pending
-
2000
- 2000-06-08 CA CA002376215A patent/CA2376215A1/en not_active Abandoned
- 2000-06-08 DE DE60022033T patent/DE60022033T2/de not_active Expired - Fee Related
- 2000-06-08 WO PCT/GB2000/002234 patent/WO2000074680A1/en not_active Ceased
- 2000-06-08 JP JP2001501216A patent/JP2003501387A/ja active Pending
- 2000-06-08 EP EP00940504A patent/EP1185268B1/en not_active Expired - Lifetime
- 2000-06-08 AU AU55432/00A patent/AU766748B2/en not_active Ceased
- 2000-06-08 AT AT00940504T patent/ATE302006T1/de not_active IP Right Cessation
- 2000-06-08 ES ES00940504T patent/ES2243273T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60022033T2 (de) | 2006-03-30 |
| GB9913458D0 (en) | 1999-08-11 |
| JP2003501387A (ja) | 2003-01-14 |
| EP1185268B1 (en) | 2005-08-17 |
| ATE302006T1 (de) | 2005-09-15 |
| AU5543200A (en) | 2000-12-28 |
| DE60022033D1 (de) | 2005-09-22 |
| WO2000074680A1 (en) | 2000-12-14 |
| EP1185268A1 (en) | 2002-03-13 |
| CA2376215A1 (en) | 2000-12-14 |
| AU766748B2 (en) | 2003-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3025836T3 (en) | Use of pridopidine for treating functional decline | |
| ES2610508T3 (es) | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo | |
| Ibach et al. | Acetylcholinesterase inhibition in Alzheimer's Disease | |
| ES3014558T3 (en) | Devices and methods for drug administration and mixing, and training of proper techniques therefor | |
| US20110034565A1 (en) | Psycho-pharmaceuticals | |
| BRPI0718323A2 (pt) | Tratamento de transtornos invasivos do desenvolvimento. | |
| ES2323451T7 (es) | Tratamiento para el trastorno de hiperactividad con deficit de atencion. | |
| US20050187196A1 (en) | Treatment of attention disorders | |
| US20250108044A1 (en) | Methods of treating depressive disorders | |
| ES2709874T3 (es) | Composiciones nootrópicas para mejorar el rendimiento de la memoria | |
| CA2708323C (en) | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder | |
| BR112020011345A2 (pt) | tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas | |
| ES2243273T3 (es) | Utilizacion terapeutica de d-treo-metilfenidato para el tratamiento del trastorno de hperactividad y deficit de atencion. | |
| AU2008254669A1 (en) | Use of pimavanserin in the treatment of parkinson and symptoms thereof | |
| Varshneya et al. | Structurally diverse fentanyl analogs yield differential locomotor activities in mice | |
| Griffin III et al. | The interactive effects of methylphenidate and ethanol on ethanol consumption and locomotor activity in mice | |
| BRPI0718318A2 (pt) | Processos para tratamento de distúrbios de perturbação de comportamento. | |
| US20230270720A1 (en) | Mavoglurant, a mglur5 antagonist, for use in the treatment in the reduction of opioid use | |
| US20090270373A1 (en) | Treatment of down syndrom with benzodiazepine receptor antagonists | |
| US20230372302A1 (en) | Prophylaxis and reversal of stimulant and opioid/opiate overdose and/or toxic exposure | |
| Garcia | The Therapeutic Potential of Serotonin 1B Receptor Agonists for Treating Psychostimulant Use Disorders | |
| BR112020004506A2 (pt) | mazindol para uso no tratamento de distúrbio de uso de substâncias, composição compreendendo mazindol, método de tratamento de distúrbio de abuso de substâncias | |
| Wilcox | RELATIONSHIP BETWEEN THE DOPAMINE TRANSPORTER AND THE REINFORCING EFFECTS OF DOPAMINE TRANSPORTER INHIBITORS IN RHESUS MONKEYS | |
| JP2021515801A (ja) | 神経変性疾患における転倒および転倒頻度に関連する処置のための組成物および方法 | |
| Thanos et al. | ÔØ Å ÒÙ× Ö ÔØ |